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STATE-OF-THE-ART REVIEW

COVID-19 Clinical Trials
A Primer for the Cardiovascular and Cardio-Oncology
Communities
Bonnie Ky, MD, MSCE,a Douglas L. Mann, MDb

HIGHLIGHTS
 SARS-CoV-2, the virus that causes COVID-19, is a novel CoV that infects humans by binding to ACE2, which degrades
angiotensin II, and hence plays a critical role in modulating the renin angiotensin system (RAS).
 The emerging epidemiology of COVID-19 suggests that patients with cardiovascular risk factors, including older age,
cardiovascular disease, or cancer may be more susceptible to infection and suffer from worse clinical outcomes.
 Because of the limited understanding with respect to the interaction of RAS inhibitors and SARS-CoV-2 infectivity, we
endorse current society recommendations to continue RAS antagonists for clinical indications for which these agents are
known to be beneﬁcial.
 Treatments for COVID-19 that are undergoing clinical trials range from therapies that block the entry of SARS-CoV-2 into
host cells, to repurposed antiviral therapies such as protease inhibitors and nucleoside analogs that block viral replication
by inhibiting viral RNA-dependent RNA polymerase.

SUMMARY
The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the
spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used
to treat patients with COVID-19 are repurposed treatments for inﬂuenza, Ebola, or for malaria that were developed
decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, the authors
provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with
COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for
the clinical trials that are ongoing for the treatment of patients with COVID-19. (J Am Coll Cardiol Basic Trans Science
2020;5:501–17) © 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ABBREVIATIONS
AND ACRONYMS
ACE = angiotensin-converting
enzyme

AT1R = angiotensin II type 1

T

disease-2019

The median duration of hospitalization was 12.0 days

(COVID-19) pandemic has resulted

(IQR: 10.0 to 14.0 days); however, the majority of the

in a proliferation of clinical trials

patients (93.6%) remained hospitalized at the time of

that are designed to slow the spread of

data analysis and as such, the clinical course still

severe

largely remains to be deﬁned.

he

acute

coronavirus

respiratory

syndrome-

receptor

coronavirus-2 (SARS-CoV-2), the virus that

COVID-19

CI = conﬁdence interval

causes COVID-19. These therapies range from

Epidemiologic data thus far suggest that patients with

vaccines, to repurposed treatments for inﬂu-

cardiovascular risk factors, including older age, car-

enza, to drugs that were not effective in pa-

diovascular disease, or cancer are more susceptible to

disease-2019

tients with Ebola, to treatments for malaria

infection and suffer from worse clinical outcomes (4).

FDA = Food and Drug

that were developed decades ago. Recog-

COVID-19 can also directly result in a number of car-

Administration

nizing that patients with underlying cardio-

diovascular

IFN = interferon

vascular risk factors, cardiovascular disease,

myocarditis, myocardial injury, heart failure, and

IL = interleukin

or cancer have an increased risk for adverse

arrhythmia (3,5,6). There have been a number of

IQR = interquartile range

outcomes with COVID-19, and recognizing

published

that these vulnerable populations may be

myocarditis as suggested by: markedly elevated

respiratory syndrome

enrolled in COVID-19 clinical trials, here we

troponin levels, ST-segment elevation on electrocar-

RAS = renin-angiotensin

present a critical review of the rationale for

diogram

system

the different therapeutics that are currently

RNA = ribonucleic acid

being employed. As background, we ﬁrst re-

severely decreased left ventricular systolic function,

sACE2 = soluble angiotensin-

view the epidemiology of COVID-19, followed

aging evidence of diffuse myocardial edema and

converting enzyme 2

by the biology of CoV. We then brieﬂy deﬁne

gadolinium enhancement (8). However, in another

SARS-CoV-2 = severe acute

the complex interplay between the CoV and

isolated autopsy report from a patient who suffered

the renin-angiotensin system (RAS), which

from SARS-CoV-2–related pneumonia and cardiac ar-

is directly relevant to the care of the

rest, no obvious histological changes in the myocar-

majority of patients with cardiovascular

dium were observed with the exception of few

disease or cancer who are receiving drugs

interstitial mononuclear inﬂammatory inﬁltrates (9).

CoV = coronavirus
COVID-19 = coronavirus

MERS = Middle East

respiratory syndromecoronavirus-2

TMPRSS2 = transmembrane
protease serine 2

AND

CARDIOVASCULAR

complications,

case

without

reports

COMPLICATIONS.

including

of

obstructive

clinically

coronary

fulminant

suspected

disease,

and shock (7), with cardiac magnetic resonance im-

that modulate this system. Finally, we review the

Elevated troponin levels have also been observed

mechanisms of action of the multiple therapies that

in those with worse clinical outcomes. In a retro-

are currently being studied in clinical trials. Given

spective, single-center analysis of 416 hospitalized

the breadth of information that is emerging, we will

patients with conﬁrmed COVID-19, 19.7% displayed

not discuss the role of vaccines.

evidence of cardiac injury, as deﬁned by elevated

EPIDEMIOLOGY OF COVID-19

high-sensitivity troponin I levels greater than the

The current impact of the novel CoV, SARS-CoV-2 is
unquantiﬁable. The number of conﬁrmed cases and
deaths from the global COVID-19 pandemic increase
daily (1,2). Although there is a great deal that still
remains to be understood, initial reports from 552
hospitals in China describing 1,099 of the 7,736 pa-

99th percentile upper limit. Those with conﬁrmed
cardiac injury tended to be older (median age of 74 vs.
60 years) and suffer from hypertension (59.8% vs.
23.4%), diabetes (24.4% vs. 12.0%), coronary heart
disease (29.3% vs. 6.0%), heart failure (14.6% vs.
1.5%), or cancer (8.5% vs. 0.6%) (10).
COVID-19 IN PATIENTS WITH CARDIOVASCULAR

tients infected with COVID-19 provide some insight

RISK FACTORS OR DISEASE. Patients with cardio-

into the disease (3). In this multicenter retrospective

vascular risk factors or disease are at increased risk of

analysis, the majority were Wuhan residents or had

suffering from worse clinical outcomes with COVID-

contact with Wuhan residents, although 25.9% were

19. In an analysis of 2 cohorts from Jinyintan Hospi-

neither. The median age of patients was 47 years

tal and Wuhan Hospital of 191 patients, patients with

(interquartile range [IQR]: 35 to 58 years), and 41.9%

hypertension, diabetes, or coronary heart disease

were female. Patients with more severe disease,

were at increased risk of in-hospital mortality (11).

compared with those with nonsevere disease, tended

The prevalence of hypertension among nonsurvivors

to be older and tended to suffer from at least 1 co-

was 48% as compared to 30% in survivors; 31% versus

morbidity. In this retrospective analysis, patients

19% for diabetes, and 13% versus 8% for cardiovas-

commonly received intravenous antibiotics (58.0%).

cular disease. These comorbidities were also more

Oseltamivir was administered in 35.8%, systemic

likely to be present in patients who required intensive

steroids in 18.6%, and oxygen in 41.3% of patients.

care unit admission (4). Other studies, including a
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recently published meta-analysis of 46,248 infected

Patients with cancer who were recently treated with

patients, have corroborated the observation that pa-

chemotherapy or surgery were also more likely to

tients with cardiovascular risk factors or cardiovas-

suffer from clinically severe adverse events. Howev-

cular disease have worse clinical outcomes (12) and

er, there is a critical need for additional studies to

also suggest that hypertension (17  7%; 95% conﬁ-

validate these early observations.

dence interval [CI]: 14% to 22%), diabetes (8  6%;
95% CI: 6% to 11%), and cardiovascular disease (5 
4%; 95% CI: 4% to 7%) were prevalent comorbidities
among infected patients. Recent studies have also
demonstrated that age and hypertension were predictors of an increased likelihood of cardiovascular
complications,

and

cardiovascular

complications

were associated with a 4.26-fold increased risk of
death (95% CI: 1.9 to 9.49) (10).
COVID-19

IN

PATIENTS

WITH

THE CoV FAMILY
CoVs represent a large family of hundreds of enveloped,

single-stranded,

positive-sense

ribonucleic

acid (RNA) viruses that establish an infection primarily by targeting the mucosal surfaces of respiratory and intestinal tracts of a wide range of mammals
and birds. There are 4 main subgroupings of CoVs:
alpha, beta, gamma, and delta (16). The 7 CoVs that

HEART

TRANS-

are capable of infecting humans include 229E (alpha

PLANTATION. There have been case series published

CoV), NL63 (alpha CoV), OC43 (beta CoV), HKU1 (beta

on COVID-19 infection in heart transplant recipients.

CoV), Middle East respiratory syndrome (MERS)-CoV

Two conﬁrmed cases suggest similar presentations to

(beta CoV), SARS-CoV (beta CoV), and SARS-CoV-2

nontransplant recipients and both patients demon-

(beta CoV). The prototype human CoV isolates 229E

strated clinical improvement. A questionnaire of 87

and OC43 have been causally linked to the common

heart transplant recipients in China, of which

cold. SARS-CoV is the cause of the SARS, whereas

importantly 96.6% undertook quarantine procedures,

MERS-CoV was established as the cause of MERS.

did not suggest a markedly elevated rate of SARS-

Identiﬁcation and sequencing of the virus responsible

CoV-2 infection in this population (13,14).

for COVID-19 established that it was a novel CoV that

COVID-19 IN PATIENTS WITH CANCER. In a retro-

spective medical review of 1,524 patients with cancer
who were admitted to the Department of Radiation
and Medical Oncology in Zhongnan Hospital of
Wuhan University from December 30, 2019, to
February 17, 2020, the infection rate of SARS-CoV-2 in
patients with cancer was 0.79% (95% CI: 0.3% to 1.2%)
(15). In contrast, the estimated cumulative incidence
of all COVID-19 cases in Wuhan was 0.37%. As a
result, the odds of infection in patients with cancer
were estimated to be 2.31 (95% CI: 1.89 to 3.02)
greater. Patients with cancer who were infected had a
median age of 66 years and were more likely to have
non–small cell lung cancer (58.3%). Five of these patients

were

being

treated

with

shared 88% sequence identity with 2 bat-derived
SARS-like CoVs (16). Subsequently, the 2019 novel
CoV was shown to share a 79.5% sequence homology
with SARS-CoV and was subsequently renamed SARSCoV-2 (16). The genome of the CoVs encodes 4 major
structural proteins: the spike (S) protein, nucleocapsid protein, membrane protein, and the envelope
protein (Central Illustration). The S protein is responsible for facilitating entry of the CoV into the target
cell (16,17) and is composed of a short intracellular
tail, a transmembrane anchor, and a large ectodomain
that consists of a receptor binding S1 subunit and a
membrane-fusing S2 subunit (16).

CoV VIROLOGY

chemotherapy,

immunotherapy, or radiation therapy. Three deaths

Given that far more is known with respect to the

were recorded.

virology of SARS-CoV than of SARS-CoV-2, and given

In a multicenter, prospective cohort study of 2,007

that these 2 CoVs appear to have some overlapping

cases from 575 hospitals, 1% of the 1,590 COVID-19

biology and clinical presentations, we will discuss

cases had a history of cancer (15). This in contrast to

these 2 viruses together, with an emphasis on the

an incidence of cancer in the Chinese population of

most recent studies that have revealed unique bio-

0.29% per 100,000 people. Again, among those

logical aspects of SARS-CoV-2. We will review viral

infected, lung cancer was most common, and patients

attachment, entry, and replication of SARS-CoV and

tended to be older. Patients with cancer also suffered

SARS-CoV-2 in host cells. This discussion will be in-

from an increased risk of adverse events that tended

tegrated with a review of the ongoing clinical trials

to occur earlier, including admission to the intensive

that target these different aspects of the biology of

care unit, need for invasive ventilation, or death,

SARS-CoV-2 (see Tables 1 to 5).

which occurred in 7 of 18 patients (39%), compared

Angiotensin-converting enzyme 2 (ACE2) is the

with 124 of 1,572 patients without cancer (8%).

entry receptor for SARS-CoV and SARS-CoV-2. Viruses
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C E N T R A L IL L U ST R A T I O N SARS-CoV-2 Structure and Entry Into Cells

Ky, B. et al. J Am Coll Cardiol Basic Trans Science. 2020;5(5):501–17.

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus genome encodes 4 major structural proteins: the spike (S) protein;
the nucleocapsid (N) protein; the membrane (M) protein; and the envelope (E) protein. The S protein is responsible for facilitating entry of the
CoV into the target cell. The routes employed by SARS-CoV include endocytosis and membrane fusion. The route employed by SARS-CoV-2
is via endocytosis; whether SARS-CoV-2 enters cells by membrane fusion is not known. Binding of the S protein of SARS-CoV to angiotensinconverting enzyme 2 (ACE2) leads to the uptake of the virions into endosomes, where the viral S protein is activated by the pH-dependent
cysteine protease cathepsin L. Activation of the S protein by cathepsin L can be blocked by baﬁlomycin A1 and ammonium chloride, which
indirectly inhibit the activity of cathepsin L by interfering with endosomal acidiﬁcation. Chloroquine and hydroxychloroquine are weak bases
that diffuse into acidic cytoplasmic vesicles such as endosomes, lysosomes, or Golgi vesicles and thereby increases their pH. MDL28170
inhibits calpain and cathepsin L. SARS-CoV can also directly fuse with host cell membranes, after processing of the virus spike protein by
transmembrane protease serine 2 (TMPRSS2), a type II cell membrane serine protease. Camostat mesylate is an orally active serine protease
inhibitor. Modiﬁed from Simmons et al. (25). RNA ¼ ribonucleic acid.

enter cells by binding to host cell-encoded proteins

activation of the RAS, by processing angiotensin I

that facilitate the entry of the virus into the cell, as

(angiotensin 1-10) to angiotensin II (angiotensin 1-8),

well as allow the virus to survive and replicate within

the major effector peptide of RAS, which mediates its

the cell. Some viruses, including certain strains of

effects through selective interactions with G-protein–

CoVs are capable of down-modulating the entry re-

coupled angiotensin II type 1 (AT1) and type 2 (AT2)

ceptor once they gain access to the cell. Receptor

receptors (19). ACE, however, has not been implicated

down-modulation is a strategy broadly used by many

in the entry of human CoVs into cells.

viruses to escape the immune system, as well as

ACE2 is highly expressed in the mouth, tongue,

establish the best environment for viral replication

and types I and II alveolar epithelial cells in the lungs.

and spread (18). Receptor down-modulation may also

ACE2 is also abundantly expressed by cardiovascular

disrupt many of the natural physiologic functions of

endothelium, cardiac myocytes, cardiac ﬁbroblasts,

the host cell, resulting in cell death leading to organ

as well as epithelial cells of the kidney and testis. The

level dysfunction.

major substrate of ACE2 is angiotensin II, which is

The entry receptor utilized by both SARS-CoV and

cleaved to angiotensin 1-7 (Figure 1) and functions

SARS-CoV-2 is ACE2 (Central Illustration), which is a

through association with the G-protein–coupled re-

type I transmembrane carboxypeptidase with 40%

ceptor Mas receptor. The ACE2–angiotensin (1–7)–Mas

homology to ACE. ACE plays a critical role in

receptor axis is regarded as the counter-regulatory

Ky and Mann
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T A B L E 1 Select Treatment Trials Targeting RAS

Drug Name

Mechanism of
Action

NCT Number

Title

Targeted
Enrollment

Study Population

Study Design

Primary Outcome
Measure

Losartan

Anti-RAS

NCT04312009

Losartan for Patients Age $18 yrs with presumptive positive laboratory
With COVID-19
test for SARS-CoV-2; admission to the hospital
Requiring
with a sequential organ failure assessment score
Hospitalization
$1 and increased oxygen requirement;
randomization within 24 h of presentation

200

Randomized, double- Difference in
blind, placebo
oxygenation
controlled
status at 7 days

Losartan

Anti-RAS

NCT04311177

Losartan for Patients Age $18 yrs with presumptive positive laboratory
With COVID-19
test for SARS-CoV-2 or URI or fever
Not Requiring
Hospitalization

516

Randomized, double- Hospital admission
blind, placebo
up to 15 days
controlled

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
COVID-19 ¼ coronavirus disease-2019; NCT ¼ national clinical trial; OFA ¼ organ failure assessment; RAS ¼ renin-angiotensin system; SARS-CoV-2 ¼ severe acute respiratory syndrome coronavirus-2;
URI ¼ upper respiratory infection.

arm of the RAS by opposing the effects of the ACE–

that SARS-CoV (23). However, monoclonal antibodies

angiotensin II axis–AT1. Although the precise role of

raised against the receptor binding domain of the S1

ACE2 is still being evaluated, studies been shown that

protein of SARS-CoV do not bind to the receptor

ACE2 exerts protective effects in the pulmonary and

binding domain of the S1 protein of SARS-CoV-2,

the cardiovascular systems, where it serves to oppose

suggesting that SARS-directed antibodies are not

the deleterious effects of RAS activation (20–22).

cross reactive and that SARS-CoV-2 proteins are

Infection with SARS-CoV and SARS-CoV-2 is trig-

necessary to develop effective antibodies. Although

gered by binding of the S protein on the surface of the

ACE inhibitors do not inhibit ACE2, Hoffman et al. (23)

CoV to ACE2 that is expressed on the cell surface. The

demonstrated that anti-ACE2 antibody prevented

receptor binding domain of the S protein of SARS-

entry of viral vectors into cell lines expressing the

CoV-2 is located on the S1 subunit, which undergoes

SARS-CoV-2 S protein.

a conformational change when it binds to ACE2,
which facilitates viral attachment to the surface of

INTERACTION OF CoV WITH THE RAS. An additional

target cells (17). Binding of SARS-CoV-2 to ACE2 can

layer of complexity to understanding the patho-

result in uptake of virions into endosomes (Central

physiology of the SARS-CoV-2 in humans stems from

Illustration). Viral entry into the cell requires prim-

the complexity of the interactions of CoVs with the

ing of the S protein by the serine protease trans-

RAS (Figure 1), as well as the widespread use of drugs

membrane protease serine 2 (TMPRSS2), which

that

cleaves the viral S protein at the S1/S2 and the S2 0 site

inhibitors,

and allows fusion of viral and cellular membranes

angiotensin receptor-neprilysin inhibitors. Each of

(23). The S proteins of SARS-CoV-2 can also use pH-

these drugs has different effects on the expression of

sensitive endosomal proteases (cathepsin B and L)

the various components of the RAS in different tissue

for priming and entry into cells. Interestingly, the

beds. Here we will brieﬂy discuss these important

binding afﬁnity of the SARS-CoV-2 S ectodomain to

interactions, as well as their implications for the

ACE2 is 10- to 20-fold higher than the binding of the

treatment of patients with COVID-19.

interfere

with

the

RAS,

angiotensin-receptor

including
antagonists,

ACE
or

SARS-CoV ectodomain to ACE2 (17). The increase in

Previous studies have shown that SARS-CoV S pro-

stickiness of the SARS-CoV-2 capsid S protein makes

teins induce the expression of a cell surface metal-

disease transmission more likely and might explain

loenzyme termed a disintegrin and metalloproteinase-

the increased person-to-person transmission with

17, which was originally described as the enzyme that

SARS-CoV-2 compared with that of SARS-CoV. Insofar

cleaves membrane-bound tumor necrosis factor-a

as the viral S proteins are the part of the virus that

from the cell surface and allows it circulate in the sol-

interacts with the immune system, they may serve as

uble form of tumor necrosis factor-a (24). As shown

a promising target for vaccines. Relevant to this dis-

in

cussion, convalescent sera from patients with SARS

metalloproteinase-17 results in the proteolytic cleav-

have been shown to block the entry of SARS-CoV-2

age of ACE2 (referred to as shedding) from the cell

entry into cultured cells, albeit with less efﬁciency

surface, with the release of the catalytically active

Figure

1,

activation

of

a

disintegrin

and
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T A B L E 2 Select Treatment and Prophylaxis Trials Targeting Viral Cell Entry

Drug Name

Mechanism of
Action

NCT Number

Title

Study Population

Targeted
Enrollment

Study Design

Primary Outcome
Measure

Treatment Trials
Camostat

Viral entry

NCT04321096

The Impact of Camostat
Age 18–110 yrs, COVID-19–
180
Mesylate on COVID-19
conﬁrmed hospitalized
Infection (CamoCo-19)
patients (<48 h) or if
hospital-acquired COVID-19
is suspected, <48 h since
onset of symptoms

Randomized, double- Time to clinical
blind placebo
improvement
controlled, phase
at 30 days
IIa trial

Hydroxychloroquine

Viral entry

NCT04315896

Age 18–80 yrs, COVID-19
Hydroxychloroquine
500
Treatment for Severe
conﬁrmed by RT-PCR in
COVID-19 Pulmonary
any respiratory sample;
Infection (HYDRA Trial)
severe disease deﬁned by
pulse O2< 91%, 3%
decline from baseline
pulse O2, or need for
increased supplemental
O2, mechanical ventilation,
or sepsis

Randomized, double- All-cause hospital
blind, placebo
mortality at
controlled
120 days

Hydroxychloroquine

Viral entry

NCT04316377

Norwegian Coronavirus
Disease 2019 Study
(NO COVID-19)

Age >18 yrs, hospitalized,
202
moderately severe disease
(NEWS score #6);
SARS-CoV-2–positive test

Randomized,
open, single arm

Rate of decline in
SARS-CoV viral load
at 96 h

Prophylaxis Trials
Chloroquine phosphate Viral entry

NCT04303507

Chloroquine/
Hydroxychloroquine
Prevention of
Coronavirus Disease
(COVID-19) in the
Healthcare Setting
(COPCOV)

40,000
Age $16 yrs; health care
worker or front-line
participant with patient
contact working in a
health care facility;
inpatient or relative of a
patient and likely exposed
to COVID-19; agree to not
self-medicate with
potential antivirals

Randomized, double- Number of
blind, placebo
symptomatic
controlled
COVID-19
infections
Severity of
symptoms

Hydroxychloroquine

Viral entry

NCT04308668

Post-exposure
Prophylaxis/Preemptive Therapy for
SARS-Coronavirus-2
(COVID-19 PEP)

Age >18 yrs; exposure to a
3,000
COVID-19 case within
4 days as either a health
care worker or household
contact; symptomatic
COVID-19 case with
conﬁrmed diagnosis within
4 days of symptom onset;
or symptomatic health
care worker with known
COVID-19 contact and
within 4 days of symptom
onset

Randomized, double- Incidence of
blind, placebo
COVID-19
controlled
disease at
14 days
Ordinal Scale of
COVID-19
disease severity
at 14 days

Hydroxychloroquine

Viral entry

NCT04318444

Hydroxychloroquine Post Age >18 yrs; household
1,600
Exposure Prophylaxis
contact of index case:
for Coronavirus Disease
currently residing in the
(COVID-19)
same household as an
individual evaluated at
NYP via outpatient, ED, or
inpatient services who:
1) tests positive for
COVID-19, or 2) is deﬁned
as suspected case, or PUI,
by the treating physician

Randomized, double- Symptomatic, labblind, placebo
conﬁrmed
controlled
COVID-19

Hydroxychloroquine

Viral entry

NCT04318015

Hydroxychloroquine
Age >18 yrs; health care
Chemoprophylaxis in
personnel exposed to
Healthcare Personnel in
patients with COVID-19
respiratory disease
Contact With COVID-19
Patients (PHYDRA
(physicians, nurses,
Trial)
chemists, pharmacists,
janitors, stretcher-bearer,
administrative, and
respiratory therapists)

Randomized, double- Symptomatic
blind, placebo
COVID-19
controlled
infection rate
at 60 days

400

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
ED ¼ emergency department; NEWS ¼ National Early Warning Score; NYP ¼ New York Presbyterian; PUI ¼ person under investigation; RT-PCR ¼ reverse transcriptase-polymerase chain reaction; other
abbreviations as in Table 1.
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soluble angiotensin-converting enzyme 2 (sACE2)

SARS-CoV-2. Given that we have limited under-

ectodomains into the circulation (22,25). A decrease in

standing with respect to the interaction of RAS in-

ACE2 levels on the cell surface would be expected to

hibitors, ACE2 levels, and SARS-CoV-2 infectivity in

result in a decrease in the levels of angiotensin 1-7

humans, we do not believe that it is possible to make

(cytoprotective) and a corresponding increase in tissue

deﬁnitive statements that go beyond the joint state-

levels of angiotensin II (proinﬂammatory and proﬁ-

ment issued on March 17, 2020, by the Heart Failure

brotic). The importance of SARS-CoV2–induced down-

Society of America, American College of Cardiology,

regulation of cell surface ACE2 was demonstrated in

and American Heart Association, that recommended

experimental studies, wherein administration of re-

“continuing

combinant human ACE2 protein, genetic deletion of

antagonists for those patients who are currently pre-

the AT1 receptor, or administration of an AT1 receptor

scribed such agents for indications for which these

antagonist were shown to be protective in acute lung

agents are known to be beneﬁcial” (33).

injury models (21,22). These and other observations

ENTRY

have suggested that the use of AT1 receptor antago-

CELLS. The entry of enveloped viruses into host cells

OF

renin-angiotensin-aldosterone

SARS-CoV

AND

SARS-CoV-2

system

INTO

nists may be beneﬁcial in patients with COVID-19 (26),

occurs through 2 primary mechanisms: the ﬁrst is

and consistent with this, losartan is currently being

direct fusion of the viral membrane with the plasma

tested in randomized, double-blind placebo controlled

membrane of the host cells, which allows the virus to

studies as a potential therapy in hospitalized infected

directly deliver its genomic material into the cytosol;

patients (Table 1). Relevant to this discussion, the ACE

and the second is that the virus hijacks the cell’s

inhibitors in clinical use do not directly affect ACE2

endocytic machinery, by binding to a cell surface

activity (27). The biological signiﬁcance of circulating

receptor, which then triggers endocytosis of the

sACE2 is not known. Of note, sACE2 retains its ability to

virus-receptor complex (Central Illustration). In the

bind the S protein of SARS-CoV and was shown to

endocytic pathway, the endocytosed virions are

prevent entry of SARS-CoV into cells in vitro (28).

subjected to an activation step within the endosome,

Thus, sACE2 may act as a decoy receptor that prevents

which is typically mediated by the acidic environ-

SARS-CoV-2 from binding to ACE2 on the cell surface.

ment of the endosome, resulting in fusion of the viral

APN01 is a human recombinant sACE2 that has been

and endosomal membranes, which allows for the

shown to block the early stages of SARS-CoV-2 in-

release of the viral genome into the cytosol. Several

fections in cell culture and human tissue organoid

viruses, including human immunodeﬁciency virus

cultures (29). APN01 has already undergone safety and

and SARS-CoV use direct membrane fusions at the

tolerability testing in a phase II trial of healthy volun-

cell surface or endocytosis to enter cells. As noted,

teers (NCT00886353), but at the time of this writing is

recent studies suggest that SARS-CoV-2 binds to

not being tested clinically in patients with COVID-19.

ACE2, which leads to endocytosis of the receptor-

The recognition that many patients with COVID-19

virus complex (23). What is not known at this time

have underlying medical conditions that are treated

is whether SARS-CoV-2 is also capable of directly

with ACE inhibitors and AT1 receptor antagonists

fusing with the lipid membrane of cells. However,

(30), coupled with the knowledge that higher urinary

based on the similarities of how SARS-CoV and SARS-

ACE2 levels have been observed in patients treated

CoV-2 behave, it is likely that their modes of entry

with AT1 receptor antagonists (26), has given rise to

into cells will be similar. Understanding these dif-

the concern that pharmacologic up-regulation of

ferences in cell entry has implications for developing

ACE2 by RAS inhibitors may inﬂuence the infectivity

novel therapeutics.

of SARS-CoV-2 in a patient population that is already
at high risk for severe COVID-19 infection (31). How-

THERAPEUTICS

ever, as noted in a recent review (32) on this topic, the

entry of SARS-CoV into cells was shown to occur by

TARGETING

ENDOCYTOSIS. The

experimental and clinical data often yield conﬂicting

direct fusion of the viral membranes with the plasma

results with respect to the role of ACE inhibitors and

membrane of the host cell (Central Illustration),

AT1 receptor antagonists on ACE2 levels in different

through a process that requires processing of the viral

pathophysiological contexts. These conﬂicting results

S protein by TMPRSS2 at or near the cell surface.

suggest that the effects on RAS inhibitors on ACE2 are

Processing of the S protein exposes the fusion peptide

complex and nuanced and should not be assumed to

of the S protein that inserts into the cell membrane,

be the same for all RAS inhibitors, nor should it be

which brings the envelope of the viral membrane into

assumed that changes in ACE2 levels in the heart or

closer approximation with the membrane of the host

other tissues necessarily reﬂect changes in ACE2

cell, thereby facilitating fusion (34). At the time of

levels in the lung, which is the portal of entry for

this writing, the uptake of SARS-CoV-2 into cells has
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T A B L E 3 Select Treatment Trials Targeting Viral Replication

Mechanism of
Action

NCT Number

Umifenovir

Antiretroviral

NCT04260594

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of
Pneumonia Caused by Novel Coronavirus

ASC09 þ ritonavir; lopinavir þ ritonavir

Antiretroviral

NCT04261907

Evaluating and Comparing the Safety and Efﬁciency of ASC09/Ritonavir and
Lopinavir/Ritonavir for Novel Coronavirus Infection

Darunavir þ cobicistat

Antiretroviral

NCT04252274

Efﬁcacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
(DC-COVID-19)

Lopinavir þ ritonavir; umifenovir

Antiretroviral

NCT04252885

Efﬁcacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus
Infection (ELACOI)

Lopinavir þ ritonavir

Antiretroviral

NCT04330690

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)

Remdesivir

Antiretroviral

NCT04280705

Adaptive COVID-19 Treatment Trial (ACTT)

Remdesivir

Antiretroviral

NCT04292899

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734)
in Participants With Severe Coronavirus Disease (COVID-19)

Remdesivir

Antiretroviral

NCT04292730

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734)
in Participants With Moderate Coronavirus Disease (COVID-19)
Compared to Standard of Care Treatment

Drug Name

Title

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
ECMO ¼ extracorporeal membrane oxygenation; FiO2 ¼ fraction of inspired O2; nCoV ¼ novel coronavirus; PaO2 ¼ partial arterial O2 pressure; PCR ¼ polymerase chain reaction; RR ¼ respiratory rate; other
abbreviations as in Tables 1 and 2.

been shown to occur through endocytosis of the

to increase endosomal pH. Inside cells, chloroquine

SARS-CoV-2–ACE2 complex, which also requires

and hydroxychloroquine are rapidly protonated and

priming of the S protein by TMPRSS2. It is not known

concentrated in endosomes. The positive charge of

whether SARS-CoV-2 also enters though direct fusion.

the chloroquine increases the pH of the endosome,

Based on the evidence linking TMPRSS2-mediated

which prevents cathepsin-induced priming of the

SARS-CoV-2 activation to SARS-CoV-2 infectivity

viral S protein. Both chloroquine and hydroxy-

(23,35), the small molecule serine protease inhibitor

chloroquine

camostat mesylate may also be an attractive target for

cultured cells; however, hydroxychloroquine is more

decrease

SARS-CoV-2

replication

in

clinical trials with SARS-CoV-2 (Table 2). Camostat

potent than chloroquine (37). In a small single-arm

mesylate has already been shown to inhibit replica-

study of patients with conﬁrmed COVID-19, treat-

tion of inﬂuenza and parainﬂuenza viruses and to

ment with hydroxychloroquine was associated with a

prevent the development of pneumonia and viral

signiﬁcant difference in clearing of viral nasopha-

myocarditis in infected mice (36). Given that the

ryngeal carriage of SARS-CoV-2 within 3 to 6 days

SARS-CoV-2 S protein is activated by the pH-

when compared with that of untreated control sub-

dependent cysteine protease cathepsin L, this pro-

jects that were studied at 3 to 6 days. Azithromycin

cessing step may be sensitive to inhibition with drugs

when added to hydroxychloroquine was signiﬁcantly

that indirectly inhibit cathepsin L activity by inter-

more efﬁcient for virus elimination (38). However,

fering with endosomal acidiﬁcation (e.g., baﬁlomycin

both therapies can result in QT prolongation, and as

A1) or by compounds that directly block the proteo-

such, caution needs to be exercised when using these

lytic activity of cathepsin L.

therapies

together.

Chloroquine

and

hydroxy-

It has also been suggested that the antimalarial

chloroquine can also manifest in cardiotoxicity,

drugs chloroquine and hydroxychloroquine might

including cardiomyopathy, both systolic and dia-

exert a potent antiviral effect by virtue of their ability

stolic, atrioventricular block, and bundle branch
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T A B L E 3 Continued

Targeted
Enrollment

Study Population

Study Design

Primary Outcome Measure

Age $18 yrs; subjects with pneumonia diagnosed as 2019-nCoV infection;
detection of 2019-nCoV nucleic acid–positive by RT-PCR in respiratory
tract or blood samples; virus gene sequence of respiratory tract or
blood samples is highly homologous to the known 2019-nCoV

380

Randomized, single-arm, open-label Negative viral conversion rate at 7 days
umifenovir

Age between 18 to 75 yrs; lab (RT-PCR) and clinically conﬁrmed case of
2019-nCoV pneumonia; hospitalized with a new onset respiratory
illness (#7 days since illness onset)

160

Randomized, open-label ASC09/
ritonavir or lopinavir/ritonavir

The incidence of adverse outcomes, deﬁned
by at least 1 of the following: pulse
O2 #93% without O2 supplementation,
PaO2-to-FiO2 ratio #300 or RR $30
breaths/min assessed at 14 days

Pneumonia caused by 2019-nCoV

30

Randomized, open-label,
single-arm

The viral clearance rate of throat swabs,
sputum, or lower respiratory tract
secretions at day 7

Age 18–80 yrs; conﬁrmation of SARS-CoV-2 infection by RT-PCR with
normal kidney and liver function

125

Randomized, open-label (1:1:1) to
lopinavir þ ritonavir; or
umifenovir; or standard care

The rate of viral inhibition, as determined by
RT-PCR at days 2, 4, 7, 10, 14, and 21

Age >6 months with conﬁrmed SARS-CoV-2 by RT-PCR, admitted to
hospital

440

Randomized, open-label (1:1) of
lopinavir þ ritonavir or
standard care

Efﬁcacy of intervention at 29 days as
determined by 10-point ordinal scale of
clinical status

Age 18–99 yrs, PCR-conﬁrmed novel coronavirus infection by lab assay;
illness as deﬁned by abnormal radiographic imaging, clinical
assessment, and pulse O2 #94%, requiring O2, or requiring mechanical
ventilation

572

Adaptive, randomized, double-blind Time to recovery at day 29
placebo controlled

Age $18 yrs; conﬁrmation of SARS-CoV-2 infection by RT-PCR #4 days
before randomization; current hospitalization with pulse O2 #94%

6,000

Randomized, open-label study of
remdesivir 5 days; or remdesivir
10 days

Odds of clinical improvement on a 7-point
ordinal scale by day 11

Age $18 yrs; conﬁrmation of SARS-CoV-2 infection by RT-PCR #4 days
before randomization; current hospitalization with fever, pulse
O2 >94%, radiographic evidence of pulmonary inﬁltrates

1,600

Randomized, open-label study of
remdesivir 5 days; or remdesivir
10 days; or standard of care

Odds of clinical improvement on a 7-point
ordinal scale by day 11

block (39). Hydroxychloroquine will be used as one of

the

the treatment arms in the World Health Organization

regarding SARS-CoV-2 replication in cells, let alone

(WHO)

multinational

SOLIDARITY

(Efﬁcacy

SARS-CoV-2

genome,

very

little

is

known

of

how the virus interacts with the host. Given that

Different Antiviral Drugs in SARS-CoV-2) trial (40)

antiviral strategies are being considered for treatment

and is also currently being investigated in a number

of patients with COVID-19, here we will review what

of other studies (Tables 2 and 5). Interestingly, amio-

is generally understood about SARS-CoV replication

darone, which is a cationic amphiphile, was shown to

in mammalian cells, recognizing that this information

inhibit Ebola virus infection in vitro in target cells,

may change as we learn more about SARS-CoV-2

using concentrations of amiodarone that overlapped

(see Figure 2).

those detected in the sera of patients treated for ar-

Once the genomic RNA of SARS-CoV is released

rhythmias. Both amiodarone and its main metabolite,

into the cytoplasm of the host cell, the positive-

monodesethyl amiodarone, were shown to interfere

strand viral RNA is translated on host ribosomes

with the fusion of the viral envelope with the endo-

into a large polypeptide termed the replicase, which

somal membrane, thus blocking viral replication (41).

undergoes proteolytic cleavage to yield proteins that

Amiodarone has also been shown to inhibit SARS-CoV

are required from genome replication, including a

infection and spreading in vitro by altering the late

viral RNA-dependent RNA polymerase. The viral

compartments of the endocytic pathway by acting

RNA-dependent RNA polymerase generates a full-

after the transit of the virus through endosomes (42).

length, antisense negative-strand viral RNA template, which is used for replicating positive strand

REPLICATION

OF

SARS-CoV

IN

HOST

CELLS.

viral genomic RNA, as well as shorter subgenomic

Because of the exceptionally large size of the CoV

negative strand RNAs that serve as templates for

RNA genome (w30 kb) and the complexity of CoV-

synthesizing messenger RNAs that code for structural

host cell interactions, coupled with the novelty of

proteins of the virus, including the S, membrane,

Ky and Mann
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T A B L E 4 Select Treatment and Prophylaxis Trials Targeting the Immune System

Drug Name

Mechanism of Action

NCT Number

Title

Study Population

Targeted
Enrollment

Primary Outcome
Measure

Study Design

Treatment Trials
IFN-a1b

Immunomodulatory

NCT04293887

Age $18 yrs with clinically
Efﬁcacy and Safety
diagnosed coronavirus
of IFN-a1b in the
Treatment of Novel
pneumonia within
Coronavirus
7 days, including
Patients
RT-PCR evidence of
coronavirus and
symptoms

328

Randomized, openlabel, single-arm

Incidence of side
effects within
14 days
including
dyspnea, pulse
O2 #94%, and
RR $24
breaths/min

Methylprednisolone

Immunomodulatory

NCT04273321

Efﬁcacy and Safety
of Corticosteroids
in COVID-19

Age >18 yrs, diagnosis of
novel coronavirus
pneumonia (COVID-19)

400

Randomized, openlabel, single-arm

Incidence of
treatment
failure in
14 days

Methylprednisolone

Immunomodulatory

NCT04244591

Glucocorticoid Therapy Age >18 yrs, RT-PCR–
for COVID-19
conﬁrmed infection,
Critically Ill Patients
symptoms for >7 days,
With Severe Acute
PaO2/FiO2 <200,
Respiratory Failure
positive pressure
ventilation or HFNC
higher than 45 l/min
for <48 h, requiring ICU
admission

80

Sarilumab

Immunomodulatory

NCT04315298

Age $18 yrs; conﬁrmation
Evaluation of the
Efﬁcacy and Safety
of SARS-CoV-2 infection
of Sarilumab in
by RT-PCR; current
Hospitalized
hospitalization with
evidence of pneumonia
Patients With
COVID-19
and severe disease,
critical disease, or
multiorgan system
dysfunction

400

Adaptive, randomized,
double-blind,
placebo-controlled
with high and low
doses

Siltuximab

Immunomodulatory

NCT04329650

Efﬁcacy and Safety
of Siltuximab vs.
Corticosteroids in
Hospitalized
Patients With
COVID-19
Pneumonia

Age $18 yrs;
conﬁrmation of
SARS-CoV-2
infection by
RT-PCR; current
hospitalization with
evidence of pneumonia;
maximum O2 support of
35%

100

Randomized, open-label Proportion of
of siltuximab or
patients
methylprednisolone
requiring ICU
admission at
29 days

Tocilizumab

Immunomodulatory

NCT04317092

Tocilizumab in COVID-19 No age or sex limit;
Pneumonia
SARS-CoV-2
(TOCIVID-19)
infection by
RT-PCR, current
hospitalization
secondary to
pneumonia; pulse
O2 #93%, requiring O2,
or requiring mechanical
ventilation (invasive or
noninvasive)

400

Open-label, single-arm Mortality at
1 month

Randomized, open-label Murray lung injury
of glucocorticoid
score at 7 days
therapy or standard
of care

Percent change in
C-reactive
protein levels
at 4 days
Percentage of
patients
reporting
clinical severity
rated on a
7-point ordinal
scale

Continued on the next page

envelope, and nucleocapsid proteins. Translation of

and maturation, virions are transported to the cell

viral messenger RNAs occurs using the host endo-

surface in vesicles and released by exocytosis (43,44).

plasmic reticulum. Once the viral structural proteins,
S, envelope, and membrane, are translated in the

THERAPEUTICS FOR VIRAL REPLICATION. There are

endoplasmic reticulum, they move along the secre-

a number of antiviral drugs that are being repurposed

tory pathway to the endoplasmic reticulum-Golgi in-

for the treatment of SARS-CoV-2. A partial list of these

termediate compartment. There, the viral proteins

antiviral drugs are discussed next.

become encapsulated and bud into membranes con-

N u c l e o s i d e a n a l o g s . Remdesivir (GS-5734, Gilead

taining viral structural proteins. Following assembly

Sciences, Inc., Foster City, California) is a nucleoside

Ky and Mann
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T A B L E 4 Continued

Drug Name

Tocilizumab

Anakinra,
siltuximab,
or tocilizumab

Mechanism of Action

Immunomodulatory

Immunomodulatory

NCT Number

NCT04320615

NCT04330638

Title

Targeted
Enrollment

Study Population

A Study to Evaluate
the Safety and
Efﬁcacy of
Tocilizumab in
Patients With
Severe COVID-19
Pneumonia
(COVACTA)

Age $18 yrs; hospitalized
with COVID-19
pneumonia per WHO
criteria; pulse O2 #93%
or PaO2/FiO2 <300

Treatment of COVID-19 Age $18 yrs; hospitalized with
Patients With Anticonﬁrmed COVID-19
interleukin Drugs
diagnosis by RT-PCR or
(COV-AID)
other laboratory test;
hypoxia deﬁned by PaO2/
FiO2; CXR or CT scan with
bilateral inﬁltrates

Study Design

Primary Outcome
Measure

330

Randomized, doubleblind placebo
controlled

Clinical status
using a
7-category
ordinal scale at
28 days

342

Randomized, open-label Time to clinical
(1:1:1:1) to anakinra,
improvement at
or siltuximab, or
15 days
anakinra þ siltuximab,
or tocilizumab, or
anakinra þ tocilizumab

Prophylaxis Trial
Recombinant human
IFN-a1b and
thymosin a1

Immunomodulatory

NCT04320238

Experimental Trial of
Age 18 to 65 yrs, formally
rhIFNa Nasal Drops
serving as medical staff
to Prevent 2019in Taihe Hospital
nCOV in Medical
Staff

2,944

2-arm, open-label to
IFN-a1b in a low-risk
group and IFN-a1b
and thymosin a1 in a
high-risk group

New COVID-19
diagnosis at
28 days

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
CT ¼ computed tomography; CXR ¼ chest x-ray; HFNC ¼ high ﬂow nasal cannula; ICU ¼ intensive care unit; IFN ¼ interferon; rhIFN ¼ recombinant human interferon; WHO ¼ World Health Organization;
other abbreviations as in Tables 1 to 3.

analog that exhibits broad antiviral activity. Remde-

Favipiravir (Avigan, Fujiﬁlm Toyama Chemical,

sivir is a prodrug that is metabolized to its active form

Tokyo, Japan) is another nucleoside analog antiviral

GS-441524, which interferes with the action of viral

drug that inhibits viral RNA-dependent RNA poly-

RNA-dependent RNA polymerase, resulting in a

merase. Like remdesivir, it is a prodrug that is

decrease in viral RNA production. It is not known,

metabolized to its active form, favipiravir-ribofur-

however, whether remdesivir terminates RNA chains

anosyl-5’-triphosphate. Although favipiravir has un-

or causes mutations in them. Remdesivir was effec-

dergone phase III clinical trials for the treatment of

tive against multiple types of CoVs in cell culture and

inﬂuenza, it is not yet approved by the U.S. Food and

a mouse model of SARS (45); however, it did not show

Drug

an effect in patients with Ebola. Remdesivir is

approval for favipiravir for treating viral strains un-

currently being tested in several clinical trials for

responsive to current antivirals. In preliminary

hospitalized patients with COVID-19 and pneumonia

studies, favipiravir was shown to have more potent

(Tables 3 and 5). Remdesivir is also 1 of the 4 treat-

antiviral activity than lopinavir/ritonavir (47).

Administration

(FDA).

Japan

has

granted

ment arms in the multinational SOLIDARITY trial,

Ribavirin (Copegus, Genentech Inc., San Francisco,

which is the World Health Organization’s sponsored

California) is a prodrug that acts as nucleoside in-

multinational randomized, open clinical trial to

hibitor. The metabolites of ribavirin resemble aden-

evaluate the safety and comparative efﬁcacy of

osine or guanosine nucleosides that then become

hydroxychloroquine, remdesivir, the combination of

incorporated

lopinavir and ritonavir, and the combination lopina-

dependent replication in RNA viruses. Ribavirin is

into

viral

RNA

and

inhibit

RNA-

vir and ritonavir plus interferon-beta (40). SOLI-

currently FDA-approved for the treatment of chronic

DARITY will use an adaptive design, which will allow

hepatitis C virus infection in combination with

for discontinuation of drugs that lack effectiveness,

peginterferon alfa-2a (Pegasys, Genentech).

as well as adding new drugs that appear promising.

P r o t e a s e i n h i b i t o r s . Lopinavir is a protease inhibi-

This type of trial design offers ﬂexibility and efﬁ-

tor class that is used in ﬁxed-dose combination with

ciency, particularly in the identiﬁcation of early sig-

another protease inhibitor, ritonavir (lopinavir/rito-

nals related to either efﬁcacy or toxicity, while

navir [Kaletra, AbbVie Inc., North Chicago, Illinois])

maintaining study validity (46).

for the treatment of human immunodeﬁciency virus.
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T A B L E 5 Select Treatment Trials With Multiple Targets

Mechanism
of Action

Drug Name

NCT Number

Title

Lopinavir þ ritonavir; ribavirin; IFN-b1b

Antiretroviral and immunomodulatory

NCT04276688

Lopinavir/Ritonavir, Ribavirin and IFN-beta Combination
for nCoV Treatment

Lopinavir þ ritonavir; hydroxychloroquine

Antiretroviral and viral entry

NCT04307693

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine
in Patients With Mild Coronavirus Disease (COVID-19)

Remdesivir þ hydroxychloroquine;
remdesivir; hydroxychloroquine

Antiretroviral and viral entry

NCT04321616

Efﬁcacy of Different Anti-viral Drugs in COVID-19 Infected
Patients

Combinations of oseltamivir, chloroquine,
Antiretroviral and viral entry
darunavir, ritonavir, lopinavir, oseltamivir,
favipiravir

NCT04303299

Various Combination of Protease Inhibitors, Oseltamivir,
Favipiravir, and Hydroxychloroquine for Treatment
of COVID19: A Randomized Control Trial (THDMSCOVID-19)

Favipiravir; chloroquine phosphate

Antiretroviral and viral entry

NCT04319900

Clinical Trial of Favipiravir Tablets Combined With
Chloroquine Phosphate in the Treatment of Novel
Coronavirus Pneumonia

Remdesivir; lopinavir þ ritonavir; IFN-b1a;
hydroxychloroquine

Antiretroviral, viral entry, and
immunomodulatory

NCT04315948

Trial of Treatments for COVID-19 in Hospitalized Adults
(DisCoVeRy)

Favipiravir þ tocilizumab

Antiretroviral and immunomodulatory

NCT04310228

Favipiravir Combined With Tocilizumab in the Treatment of
Corona Virus Disease 2019

For an up-to-date listing of trials, search for “COVID-19” at the ClinicalTrials.gov website.
IL ¼ interleukin; other abbreviations as in Tables 1 to 4.

Results from a randomized, open-label study of 199

difference: 5.8%; 95% CI: 17.3% to 5.7%), as was

hospitalized adult patients with conﬁrmed SARS-

the detectable viral load. However, there were some

CoV-2 infection assigned 1:1 to lopinavir 400 mg–

suggestions of potential beneﬁt with lopinavir/rito-

ritonavir 100 mg twice daily for 14 days with stan-

navir with a shorter intensive care unit stay (median:

dard of care or standard of care alone were recently

6 days vs. 11 days) and a shorter time to hospital

published (48). All patients had an oxygen saturation

discharge (median: 12 days vs. 14 days). As noted, the

of 94% on room air or a ratio of partial pressure of

ﬁxed-dose combination of lopinavir/ritonavir is 1

oxygen to the fraction of inspired oxygen <300

treatment arm in the SOLIDARITY trial (Table 3) (40).

mg Hg. The primary endpoint was time to clinical
was

IMMUNOMODULATORY THERAPIES. Interferons (IFNs)

deﬁned based on an ordinal scale or survival from the

are cytokines that activate the innate immune system

hospital. The study was designed for 80% power with

in response to viral infection. Type I interferons (IFN-

improvement,

where

clinical

improvement

a 2-sided signiﬁcance level of a of 0.05 to detect an 8-

a/ b) are synthesized by most cell types in the body

day difference in median time to clinical improve-

response to a viral infection, whereas type II inter-

ment. Here, the median time to clinical improvement

feron (IFN- g) is produced by immune cells following

was 16.0 days (IQR: 13.0 to 17.0 days) in the lopinavir/

antigen stimulation. Both type I and type II IFNs

ritonavir group compared with 16.0 days (IQR: 15.0 to

provoke the synthesis of proteins that have antiviral

18.0 days) with standard care. The mortality at

and immunomodulatory effects. Recombinant IFN- b

28 days in the treatment group was similar to that

has been shown to inhibit SARS-CoV replication

observed in the standard care group (19.2% vs. 25%;

in vitro more effectively than either IFN- a or IFN-g
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T A B L E 5 Continued

Targeted
Enrollment

Study Population

Study Design

Primary Outcome Measure

Age $18 yrs hospitalized for virologically
conﬁrmed 2019-nCoV infection with NEWS $1
on recruitment; febrile with symptoms and
duration of symptoms #10 days

127

Randomized, open-label (1:1:1) to lopinavir þ
ritonavir; or ribavirin; or IFN-b1b

Time to negative nasopharyngeal viral RT-PCR
assessed up to 1 month

Age 16–99 yrs with conﬁrmed mild COVID-19
(NEWS 0–4)

150

Randomized, open-label (1:1:1) lopinavir þ ritonavir;
or hydroxychloroquine; or standard care

Viral load at hospital days 3, 5, 7, 10, 14, 18

Age $18 yrs with conﬁrmed SARS-CoV-2 by
RT-PCR, admitted to hospital or ICU

700

Randomized, Open-Label (1:1:1) remdesivir; or
hydroxychloroquine; or remdesivir þ
hydroxychloroquine adaptive controlled design;
comparison with standard of care

In-hospital mortality at 3 weeks

Age 16–100 yrs with COVID-19 diagnosis

320

Randomized, open-label, oseltamivir þ chloroquine;
or darunavir þ ritonavir þ oseltamivir; or
lopinavir þ ritonavir þ oseltamivir; or
favipiravir þ lopinavir þ ritonavir; or darunavir þ
ritonavir þ oseltamivir þ chloroquine; or
darunavir þ ritonavir þ favipiravir þ chloroquine

Time to negative detection of SARS-CoV-2 in
nasopharyngeal swab at 24 weeks

Age 18–75 yrs; diagnosed with nCoV pneumonia
with a course of illness no more than 14 days;
if the course is >14 days, no progression by
chest radiograph within 7 days; respiratory
symptoms; positive COVID-19 RT-PCR within
3 days

150

Randomized, double-blind 3-arm study of
favipiravir þ chloroquine; or favipiravir; or
placebo

Time to improvement of respiratory symptoms
Number of days of viral shedding
Frequency of improvement of respiratory
symptoms

Age $18 yrs, laboratory-conﬁrmed SARS-CoV-2
infection as determined by RT-PCR or other
assay <72 h prior to randomization,
hospitalized patients with illness of any
duration, and pulmonary exam abnormalities
and pulse O2 # 94%, requiring O2, or
requiring mechanical ventilation, or acute
respiratory failure requiring mechanical
ventilation and/or supplemental O2

3,100

Adaptive, randomized, open-label 1:1:1:1:1 to
remdesivir; or lopinavir/ritonavir; or lopinavir/
ritonavir þ INF-b1a; or hydroxychloroquine; or
standard of care

Percentage of subjects reporting disease severity
on a 7-point ordinal clinical scale reﬂective of
hospitalization and oxygenation status; or
death at 15 days

Age 18–65 yrs, COVID-19 diagnosis,
increased IL-6

150

Randomized, open-label (1:1:1) of favipiravir þ
tocilizumab; or favipiravir; or tocilizumab

Clinical cure rate at 3 months

(49,50). Interestingly, IFN-g down-regulates the

treatment of severe cytokine release syndrome in

expression of ACE2 on the cell surface and protects

patients treated with chimeric antigen receptor T-cell

type I pneumocytes from SARS-CoV infection (51).

therapy and is also approved for the treatment of

The combination of lopinavir/ritonavir and IFN-b 1b is

rheumatoid arthritis (55–58). Tocilizumab is a mono-

being evaluated in the treatment of laboratory-

clonal antibody that binds the IL-6 receptor, both the

conﬁrmed MERS requiring hospitalization (52) and

membrane-bound and soluble forms, thus inhibiting

will also be evaluated in the SOLIDARITY trial (40).

both classic and trans-IL-6 downstream signaling.

A number of additional immunomodulatory agents

Similarly, the IL-6 humanized murine chimeric

are also currently being evaluated, including the

monoclonal antibody siltuximab, although not FDA-

interleukin (IL)-6 inhibitor, tocilizumab, and gluco-

approved for the treatment of cytokine release syn-

corticosteroids (Tables 4 and 5), given the cytokine

drome, has also been used in the treatment of cyto-

storm syndrome that has been observed in subgroups

kine release syndrome and is also being studied as a

with severe COVID-19 (53) with increased levels of

potential therapy in severe COVID-19 infections. Sil-

IL-2, IL-6, IL-7, and additional inﬂammatory cyto-

tuximab (Sylvant, Janssen Biotech Inc., Horsham,

kines (54). One meta-analysis suggested that the

Pennsylvania) binds directly to IL-6 and prevents the

mean IL-6 levels were 2.9-fold (95% CI: 1.17 to 7.19-

activation of immune effector cells. Sarilumab (Kev-

fold) greater in patients with complicated compared

zara, Sanoﬁ US, Bridgewater, New Jersey) is a human

with noncomplicated COVID-19 (54). Tocilizumab

monoclonal antibody against the IL-6 receptor that

(Actemra,

was developed for the treatment of rheumatoid

Genentech)

is

FDA-approved

for

the
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F I G U R E 1 Interaction of CoVs With the RAS

Angiotensin-converting enzyme (ACE) converts angiotensin I (ANG1) (angiotensin 1-10) to angiotensin II (ANG2) (angiotensin 1-8), which is
the major effector peptide of the renin-angiotensin system (RAS). ANG2 mediates its effects through selective interactions with G-protein–
coupled angiotensin II type 1 receptor (AT1R) and G-protein–coupled angiotensin II type 1 type 2 receptor (AT2R). ANG2 is degraded to
ANG-(1-7) by angiotensin-converting enzyme 2 (ACE2), ANG-(1-7) binds to the Mas receptor (not shown). The ACE2–ANG-(1-7)–Mas receptor
axis opposes the effects of ACE–ANG2–AT1 axis. The binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike
protein to ACE2 induces ACE2 shedding by activating a disintegrin and metalloproteinase-17 (ADAM-17). A decrease in ACE2 levels would be
expected to result in a decrease in the levels ANG-(1-7) levels (cytoprotective) and a corresponding increase in tissue levels of ANG2
(proinﬂammatory and proﬁbrotic). Transmembrane serine protease 2 (TMPRSS2), a type II cell membrane serine protease that activates the
spike protein of SARS-CoV-2 and allows it to bind to ACE2. Modiﬁed from Simmons et al. (25). CoVs ¼ coronaviruses; P ¼ phosphorylation.

arthritis that is also being evaluated for severe

care providers. Given that the vast majority of pa-

COVID-19.

tients with cardiovascular disease are at high risk

There are no systematically obtained clinical data

for SARS-CoV-2 infection, the cardiovascular and

yet that support a beneﬁt to the use of steroids, and

cardio-oncology communities will play a major

some reports have suggested a possible detriment

role in caring for patients with COVID-19 now and for

with delayed viral clearance and increased risk of

the foreseeable future. As a community, we have a

infection with MERS and SARS, although the role of

long tradition of enrolling patients into clinical

steroids in COVID-19 is an area of active investigation

trials

(Table 4) (59).

mechanisms of action are familiar, which facilitates

that

evaluate

therapeutic

agents

whose

reaching clinical equipoise when enrolling patients

COVID-19 AND CARDIOVASCULAR DISEASE

in clinical trials. In the coming months, our communities will be asked to contribute patients to

The COVID-19 pandemic has presented innumerable

clinical trials where the mechanisms of action of the

challenges to health care organizations and health

therapeutic

agents

are

less

familiar

and

the
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F I G U R E 2 The Replication Strategy of SARS-CoV

(a) The severe acute respiratory syndrome coronavirus (SARS-CoV) spike (S) glycoprotein attaches to the angiotensin-converting enzyme 2
(ACE2) receptor on the cell surface. On entering the cytoplasm, the viral core particle, which contains the positive (50 to 30 ) strand genomic
ribonucleic acid (RNA), is released into the cytoplasm of the cell (b). The positive-strand viral RNA is translated on host ribosomes to generate
a large polyprotein (c) that undergoes proteolytic processing to generate multiple viral proteins, including an RNA-dependent RNA polymerase (RdRp). The RNA-dependent RNA polymerase generates a full-length, antisense negative-strand (30 to 50 ) viral RNA strand (d) that
serves as template for replicating positive-strand viral genomic RNA, as well as shorter negative-strand RNAs (e) that serve as templates for
synthesizing messenger ribonucleic acids (mRNAs) that code for structural proteins of the virus (f), including the S, membrane (M), envelope
(E), and nucleocapsid (N) proteins. Translation of viral mRNAs occurs using the host endoplasmic reticulum (ER) (g). Once the viral structural
proteins, S, E, and M, are translated and inserted into the ER, they move along the secretory pathway to the endoplasmic reticulum-Golgi
intermediate compartment (ERGIC) (h). The viral proteins become encapsulated and bud into membranes containing viral structural proteins,
where mature virions are assembled. (i) Following assembly, virions are transported to the cell surface in vesicles and released by exocytosis.
Modiﬁed from Turner et al. (43). ORF ¼ open reading frame.

knowledge base required for providing care for

understand the emerging cardiovascular epidemi-

COVID-19 is accelerating at a dizzying pace. Here we

ology

have tried to provide a foundation for physicians

rationale for the plethora of clinical trials that are

who are on the front line of providing care to pa-

either being designed or are currently recruiting

tients with COVID-19, so that they can better

patients.

of

COVID-19,

as

well

as

the

biological
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